alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM A-FEM
MEDICAL CORPORATION'S FORM 10-QSB FOR THE QUARTER ENDED JUNE 30, 1999 AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               JUN-30-1999
<CASH>                                             130
<SECURITIES>                                         0
<RECEIVABLES>                                       36
<ALLOWANCES>                                         0
<INVENTORY>                                         81
<CURRENT-ASSETS>                                   420
<PP&E>                                           1,259
<DEPRECIATION>                                   (585)
<TOTAL-ASSETS>                                   1,214
<CURRENT-LIABILITIES>                              844
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                         62
<COMMON>                                            95
<OTHER-SE>                                         205
<TOTAL-LIABILITY-AND-EQUITY>                     1,214
<SALES>                                             44
<TOTAL-REVENUES>                                    44
<CGS>                                              128
<TOTAL-COSTS>                                      128
<OTHER-EXPENSES>                                 1,243
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                  41
<INCOME-PRETAX>                                (1,349)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (1,349)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (1,349)
<EPS-BASIC>                                     (0.14)<F1>
<EPS-DILUTED>                                   (0.14)<F1>
<FN>
<F1>*This information has been prepared in accordance with SFAS No. 128. Basic and
diluted EPS have been entered in place of primary and fully diluted EPS,
respectively.
</FN>


</TABLE>
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 09-8224

PRINCIBE LAGUERRE,

Plaintiff - Appellant,

v.

MELISA WHITE GAY, Esquire,

Defendant - Appellee.

Appeal from the United States District Court for the District of 

South Carolina, at Columbia. Patrick Michael Duffy, Senior

District Judge. (3:09-cv-01864-PMD)

Submitted: March 16, 2010 Decided: March 24, 2010

Before NIEMEYER, MOTZ, and DAVIS, Circuit Judges.

Affirmed by unpublished per curiam opinion.

Princibe Laguerre, Appellant Pro Se.

Unpublished opinions are not binding precedent in this circuit.
2

PER CURIAM:

Princibe Laguerre appeals the district court’s order 

accepting the recommendation of the magistrate judge and denying 

relief without prejudice on his 42 U.S.C. § 1983 (2006) 

complaint. We have reviewed the record and find no reversible 

error. Accordingly, we affirm for the reasons stated by the 

district court. Laguerre v. Gay, No. 3:09-cv-01864-PMD (D.S.C. 

filed Nov. 19, 2009; entered Nov. 20, 2009). We dispense with 

oral argument because the facts and legal contentions are 

adequately presented in the materials before the court and 

argument would not aid the decisional process.

AFFIRMED
* Pursuant to 5TH CIR. R. 47.5, the court has determined that

this opinion should not be published and is not precedent except

under the limited circumstances set forth in 5TH CIR. R. 47.5.4.

United States Court of Appeals

Fifth Circuit

FILED

May 4, 2006

Charles R. Fulbruge III

Clerk

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 05-10788

Summary Calendar

UNITED STATES OF AMERICA,

Plaintiff-Appellee,

versus

ANDRE BERNARD DAVIS,

Defendant-Appellant.

--------------------

Appeal from the United States District Court

for the Northern District of Texas

USDC No. 4:02-CR-77-ALL

--------------------

Before BARKSDALE, STEWART, and CLEMENT, Circuit Judges.

PER CURIAM:*

Andre Bernard Davis appeals the sentence of 12 months

imposed following the revocation of his supervised release. 

Davis’s sentence, which did not exceed the advisory range set

forth in U.S.S.G. § 7B1.4, was not imposed in violation of law

and was neither unreasonable nor plainly unreasonable under the

facts of this case. See United States v. Hinson, 429 F.3d 114,

119-20 (5th Cir. 2005), cert. denied, U.S. , (No. 05-

9633), 2006 WL 622263 (Apr. 17, 2006).
No. 05-10788

-2-

We review Davis’s contention that the district court erred

by failing to consider the factors set forth in 18 U.S.C. 

§ 3553(a) for plain error. See United States v. Gonzalez, 250

F.3d 923, 930 (5th Cir. 2001). The district court stated on the

record that a 12-month sentence was necessary for punishment and

deterrence, and the sentence was not unlawful. Accordingly,

there is no reversible plain error. See id. at 931.

For the foregoing reasons, the judgment of the district

court is AFFIRMED.
# C o u rt o f

A p p ea ls

o f t h e S t a te o f

G eo rg ia

ATLANTA,_

_ _ __ _ _ __ _ __ _ _ _ _ _ __ _

Th e Co u rt

o f Ap p ea l s h er eb y p a s s es t h e f

o ll owi n g o r der :

A1 6 D0 47 9 . EARL V. PARRI SH v . THE STATE.

In 1 9 9 7, Earl V. Parri s h co n v i ct ed o f rap e an d s en t en ced t o l i fe i n pri s o n

. H i s

c o n v i ct i o n was affi rm ed on ap p eal

. See Pa r ri s h v. S t a t e , 2 3 7 Ga. Ap p. 2 7 4 (5 1 4

SE2 d 45 8 ) (1 9 9 9 ). Parri sh s u b s eq u en t l y fi led an “ Ex t rao rd i n ary M o t i o n fo r New

Tri al ,” w h i ch t h e t ri al co u rt d en i ed i n an o rd er d at ed M arch 31

, 20 1 6

. Parri s h t h e n

fi led t hi s ap p l i cat i o n fo r d is cret i o n ary ap peal o n J u l y 2 6

, 2 0 16 s eek i n g rev iew o f t h at

o rd er. W e, h o wev er, l ack ju ri s d i ct i o n

. An ap p l i cat io n f

o r d i s cret i on ary ap peal m u s t b e fi l ed w i th i n 3 0 d ay s o f t h e

e n t r y o f t h e ord er o r ju dg m en t t o b e ap p eal ed

. See OCGA § 5 -6 -3 5 (d ). T h e

req u i rem en t s o f OCGA § 5 -6 -3 5 are ju ri s d i ct i o nal

, an d th i s Co urt can no t accep t an

ap p li cat io n fo r ap peal m ad e b ey o n d 3 0 d ay s

. See Bo yl e v. S ta t e , 19 0 Ga. Ap p

. 7 3 4,

7 3 4 (3 80 SE2 d 5 7 ) (1 9 89 ). Here, Parri s h fi l ed h is ap p l i cat i o n 1 17 d ay s aft er t h e t ri al

c o urt 's o rd er was en t ered

. A cco rd i n g l y , t h e ap p l i cat i o n i s u n t i m el y an d i s h ereb y

DISM ISSED fo r l ack o f ju ri s d i ct i o n

.

C o u r t o f A p p e a l s o f t h e S t a t e o

f G e o r g ia

C le r k ’ s O f f i c e

, A t la n t a

,

_

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ I c e r t i f y t h a t t h e a b o v e i s a t r u e e x t r a c t f r o m

t h e m i n u t e s o

f t h e C o u r t o

f A p p e a l s o f G e o r g i a

. W i tn e s s m y s i g n a t u r e a n d t h e s e a l o

f s a i d c o u r t

h e r e t o a f f i x e d t h e d a y a n d y e a r l a s t a b o v e w r i t t e n

.

, C l e r k

. 08/11/2016 August 11, 2016
§ 884.2620 Fetal electroencephalographic monitor. ( a ) *Identification.* A fetal electroencephalographic monitor is a device used to detect, measure, and record in graphic form (by means of one or more electrodes placed transcervically on the fetal scalp during labor) the rhythmically varying electrical skin potentials produced by the fetal brain.
( b ) *Classification.* Class III (premarket approval).
( c ) *Date PMA or notice of completion of a PDP is required.* A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any fetal electroencephalographic monitor that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to a fetal electroencephalographic monitor in commercial distribution before May 28, 1976. Any other fetal electroencephalographic monitor shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
[45 FR 12684, Feb. 26, 1980, as amended at 52 FR 17741, May 11, 1987; 61 FR 50708, Sept. 27, 1996]
Exhibit 10.36  


[PDS
LETTERHEAD] 


February 10,
2003 


Johan
P. Finley

Chief Executive Officer

PDS Gaming Corporation

6171 McLeod Drive

Las Vegas, Nevada 89120 



Dear
Johan: 


        As
you know, the Employment Agreement, dated February 1, 1998, between PDS Gaming Corporation, a Minnesota corporation (the "Company"), and yourself (the "Agreement"), had a
five-year term that ended on January 31, 2003. The Board of Directors of the Company, upon the recommendation of the Compensation Committee of the Board, has approved a resolution
(i) authorizing an extension of the term of your employment thereunder, with the modifications set forth below, for an additional two-year period ending January 31, 2005, and
(ii) authorizing the undersigned to execute, on behalf of the Company, this letter agreement to so provide. Accordingly, upon your countersignature in the space provided below, the Agreement
shall be amended, effective as of January 31, 2003, as follows: 




1.    Section 3
of the Agreement shall be restated in its entirety to read as follows: 


"3.
Term. The term of employment ("Term of Employment" or "Term") shall commence February 1, 1998, and shall continue for seven (7) years
unless terminated by either party pursuant to the terms of this Agreement." 


2.    The
last paragraph of Section 7 of the Agreement shall be restated in its entirety to read as follows: 


"If
during the Term of Employment, Employer is sold either through a transaction involving the sale of a majority of Employer's stock to a single purchaser (or to a group of purchasers) or through a
transaction involving the sale of the majority of Employer's assets, then, subject to the next sentence, Employer shall pay to Employee a Sale Bonus equal to $250,000, which shall be payable in a
single payment due within 30 days of completion of the sale. Notwithstanding the preceding sentence, if Employee (or a group that includes Employee) enters into an agreement with Employer that
provides for the payment to Employee (or any such group) of any break-up fee, termination fee, topping fee or any similar payment (a "Break-up Fee") in the event a sale
transaction is consummated with a party other than Employee (or such group), then the amount of any Sale Bonus payable to Employee shall be reduced (but not below zero) by the amount of any
Break-up Fee payable to Employee (or any such group)." 





        All
other provisions of the Agreement shall remain in full force and effect. 



	 	 	Very truly yours,
	

 	
 	

/s/  PETER D. CLEARY      
 Peter D. Cleary

President and Chief Operating Officer
	

ACCEPTED AND AGREED

AS OF JANUARY 31, 2003:

	
 	

 
	

/s/  JOHAN P. FINLEY      
 Johan P. Finley
# C_2015107EN.01001402.xml

| 30.3.2015 | EN | Official Journal of the European Union | C 107/14 |
| --- | --- | --- | --- |

30.3.2015

EN

Official Journal of the European Union

C 107/14

---

Appeal brought on 2 July 2014 by Ms Galina Meister against the order of the General Court (Fourth Chamber) delivered on 5 December 2013 in Case T-390/13 Galina Meister v European Commission

(Case C-327/14 P)

(2015/C 107/19)

Language of the case: German

Parties

Appellant: Galina Meister (represented by: W. Becker, Rechtsanwalt)

Other party to the proceedings: European Commission

The Court of Justice of the European Union (Sixth Chamber) dismissed the appeal by order of 12 February 2015 and ordered the appellant to bear her own costs.

---
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
This schedule contains summary financial information extracted from Swift Energy
Income Partners 1986-D, Ltd.'s balance sheet and statement of operations con-
tained in its Form 10-Q for the quarter ended March 31, 1997 and is qualified in
its entirety by reference to such financial statements.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                              DEC-31-1997
<PERIOD-END>                                   MAR-31-1997
<CASH>                                         29,111
<SECURITIES>                                   0
<RECEIVABLES>                                  231,762
<ALLOWANCES>                                   0
<INVENTORY>                                    0
<CURRENT-ASSETS>                               260,873
<PP&E>                                         12,903,273
<DEPRECIATION>                                 (10,569,011)
<TOTAL-ASSETS>                                 2,595,135
<CURRENT-LIABILITIES>                          79,652
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       0
<OTHER-SE>                                     2,389,172
<TOTAL-LIABILITY-AND-EQUITY>                   2,595,135
<SALES>                                        154,519
<TOTAL-REVENUES>                               156,342
<CGS>                                          0
<TOTAL-COSTS>                                  91,441<F1>
<OTHER-EXPENSES>                               0
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             0
<INCOME-PRETAX>                                32,305
<INCOME-TAX>                                   0
<INCOME-CONTINUING>                            32,305
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   32,305
<EPS-PRIMARY>                                  0
<EPS-DILUTED>                                  0
<FN>
<F1>Includes lease operating expenses, production taxes and depreciation,
depletion and amortization expense.  Excludes general and administrative and
interest expense.
</FN>
        


</TABLE>
# C_2015354EN.01003601.xml

| 26.10.2015 | EN | Official Journal of the European Union | C 354/36 |
| --- | --- | --- | --- |

26.10.2015

EN

Official Journal of the European Union

C 354/36

---

Judgment of the General Court of 10 September 2015 — Laverana v OHIM (BIO PROTEINREICHER PFLANZENKOMPLEX AUS EIGENER HERSTELLUNG)

(Case T-571/14) (1)

1

((Community trade mark - Application for Community figurative mark BIO PROTEINREICHER PFLANZENKOMPLEX AUS EIGENER HERSTELLUNG - Absolute ground for refusal - Descriptive character - Article 7(1)(c) of Regulation (EC) No 207/2009))

(2015/C 354/42)

Language of the case: German

Parties

Parties

Applicant: Laverana GmbH & Co. KG (Wennigsen, Germany) (represented by: J. Wachinger, M. Zöbisch and D. Chatterjee, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: A. Schifko, acting as Agent)

Defendant:

Re:

Re:

Action brought against the decision of the Fourth Board of Appeal of OHIM of 27 May 2014 (Case R 125/2014-4) concerning an application for registration of the figurative sign BIO PROTEINREICHER PFLANZENKOMPLEX AUS EIGENER HERSTELLUNG as a Community trade mark.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Laverana GmbH & Co. KG to bear the costs. |
| --- | --- |

2.

Orders Laverana GmbH & Co. KG to bear the costs.

---

(1)  OJ C 361, 13.10.2014.

1

---
#### Robert Millette *v.*Frederick G. Reincke, Warden, Connecticut State Prison

King, C. J., Alcorn, House, Thim and Ryan, Js.

Argued February 6

decided February 6, 1969

*Arnold H. Klau,*special public defender, for the appellant (plaintiff).

*Thomas F. Wall,*state’s attorney, for the appellee (defendant).

*603Per Curiam.

The judgment is affirmed on the authority of *Reed*v. *Reincke,*155 Conn. 591, 236 A.2d 909, *D’Amico*v. *Reincke,*155 Conn. 627, 236 A.2d 914, *State*v. *Gyuro,*156 Conn. 391, 394, 242 A.2d 734, and *Williams*v. *Reincke,*157 Conn. 143, 147, 249 A.2d 252.

There is no error.
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.6020 Immunomagnetic circulating cancer cell selection and enumeration system. ( a ) *Identification.* An immunomagnetic circulating cancer cell selection and enumeration system is a device that consists of biological probes, fluorochromes, and other reagents; preservation and preparation devices; and a semiautomated analytical instrument to select and count circulating cancer cells in a prepared sample of whole blood. This device is intended for adjunctive use in monitoring or predicting cancer disease progression, response to therapy, and for the detection of recurrent disease.
( b ) *Classification.* Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Immunomagnetic Circulating Cancer Cell Selection and Enumeration System.” See § 866.1(e) for availability of this guidance document.
[69 FR 26038, May 11, 2004]
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5240 Complement components immunological test system. ( a ) *Identification.* A complement components immunological test system is a device that consists of the reagents used to measure by immunochemical techniques complement components C1q, C1r, C1s, C2, C3, C4, C5, C6, C7, C8, and C9, in serum, other body fluids, and tissues. Complement is a group of serum proteins which destroy infectious agents. Measurements of these proteins aids in the diagnosis of immunologic disorders, especially those associated with deficiencies of complement components.
( b ) *Classification.* Class II (performance standards).
[47 FR 50823, Nov. 9, 1982, as amended at 53 FR 11253, Apr. 6, 1988]
Editorial Note on Part 882
Editorial Note: Nomenclature changes to part 882 appear at 73 FR 35341, June 23, 2008.

§ 882.5803 Digital therapy device for Attention Deficit Hyperactivity Disorder. ( a ) *Identification.* A digital therapy device for Attention Deficit Hyperactivity Disorder (ADHD) is a software intended to provide therapy for ADHD or any of its individual symptoms as an adjunct to clinician supervised treatment.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Clinical performance testing must demonstrate and document the following under the labeled conditions for use, which include considerations for the ability of the device to: ( i ) Use a validated measure to evaluate effectiveness of device to provide therapy for ADHD or any of its individual symptoms; and
( ii ) Capture all adverse events.
( 2 ) Software must be described and provided in a clear and detailed manner to include all features and functions of the software implementing the digital therapy. Software verification, validation, and hazard analysis must also be provided.
( 3 ) The labeling must include the following items: ( i ) Patient and physician labeling must include instructions for use, including images that demonstrate how to interact with the device;
( ii ) Patient and physician labeling must list the minimum operating system (OS) requirements that support the software of the device;
( iii ) Patient and physician labeling must include a warning that the digital therapy device is not intended for use as a standalone therapeutic device;
( iv ) Patient and physician labeling must include a warning that the digital therapy device does not represent a substitution for the patient's medication; and
( v ) Physician labeling must include a summary of the clinical performance testing conducted with the device.
[89 FR 71156, Sept. 3, 2024]
Exhibit 32.1


                           CERTIFICATION PURSUANT TO
                            18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


 In connection with the  Quarterly  Report  of  Home  Products International,
 Inc.  (the  "Company") on  Form 10-Q  for the period ended  June 28, 2003 as
 filed with the  Securities and Exchange Commission  on  August 11, 2003,  I,
 James  R. Tennant, Chief Executive Officer and Chairman  of the Board of the
 Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to
 section 906 of the Sarbanes-Oxley Act of 2002, that:

 (1)  The Report fully complies with the requirements of section 13(a) or
      15(d) of the Securities Exchange Act of 1934; and

 (2)  The information contained in the Report fairly presents, in all
      material respects, the financial condition and results of operations of
      the Company.


  /s/ JAMES R. TENNANT
  --------------------
  James R. Tennant
  Chief Executive Officer and Chairman of the Board
  August 11, 2003


 A signed original of this written statement required by Section 906 has been
 provided to Home Products International, Inc.  and will be retained by  Home
 Products International, Inc.  and furnished to  the Securities and  Exchange
 Commission or its staff upon request.
|Exhibit 99.1



Certification Pursuant to 
18 U.S.C. Section 1350 As Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002


The
undersigned certifies, pursuant to 18 U.S.C. Section 1350, that:
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(1) | The accompanying Quarterly Report on Form 10-Q for the period ended December 31,
          2002, fully complies with the requirements of Section 13(a) or 15(d) of the
          Securities Exchange Act of 1934; and
|--- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(2) | The information contained in the accompanying Report fairly presents, in all
          material respects, the financial condition and results of operations of the
          Company.
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Date: February 4, 2003 | By: s/ Marti MorfittMarti MorfittPresident
& Chief Executive Officer                        
|---------------------- | --------------------------------------------------------------------------------------------
|                      
|                       | By: s/ David J. ByrdDavid J. Byrd
President of Finance, ChiefFinancial Officer and Treasurer